The price of a medical procedure is often a mystery until the bill arrives, a source of patient anxiety and financial strain that persists despite a federal rule requiring hospitals to publish their prices. A new Boston-based project, rede.care, is betting that the problem is not a lack of data, but a lack of clarity. Founded in 2026 by Andrew Magown, the company is building a consumer-facing tool that aims to read those legally mandated price files, apply an individual’s insurance plan, and show the potential out-of-pocket cost for every facility nearby on a map [rede.care, retrieved 2024]. Its stated ethos is to show when a price is unavailable rather than invent a figure, a small but meaningful nod to the trust deficit in healthcare navigation.
The wedge of honest uncertainty
Rede’s apparent product wedge is a focus on procedural honesty over algorithmic guesswork. In a market where price transparency tools often generate estimates, rede.care’s public materials emphasize sourcing and labeling. The tool promises to organize pricing information across providers, insurers, and public programs, using what it describes as AI-assisted development for source verification [LinkedIn, retrieved 2024]. The core user journey is split into two phases: finding a price before care, and then having the tool read a resulting bill back line-by-line for verification [rede.care, retrieved 2024]. For a patient facing a scheduled MRI or a new prescription, the value proposition is a map of concrete, sourced prices instead of a range of estimates.
The founder’s path from CRM to care
The venture is a solo endeavor led by Andrew Magown, who lists a September 2026 start date for Rede on his public profile [LinkedIn, retrieved 2024]. His background is in customer relationship management systems, having served as VP of CRM Development at InterWeave, a Boston-area integration technology firm [LinkedIn, retrieved 2024]. This experience suggests a founder oriented around system interoperability and user-facing data presentation, which are central challenges in aggregating disparate hospital price files. The company is headquartered in Boston, a hub for both healthtech and the complex insurance markets that define U.S. healthcare costs.
Navigating a crowded and complex field
Rede enters a competitive landscape populated by established players with varying business models. Its success will depend on achieving a clarity and user experience that incumbents have not. The competitive set includes:
- Turquoise Health and Healthcare Bluebook, which aggregate published price data for both consumers and enterprise clients.
- FAIR Health, a non-profit that licenses its data for use in cost estimation tools.
- MDsave and New Choice Health, which focus on packaged, cash-pay prices for specific procedures.
Rede’s stated differentiator is its end-to-end, plan-aware mapping for the individual consumer, a B2C approach in a field with many B2B data licensors. However, the technical and regulatory hurdles are significant. Hospital compliance with transparency rules is inconsistent, and the files themselves are notoriously messy. Integrating with hundreds of insurer plan designs to model patient responsibility is a monumental data engineering task that has stalled larger, better-funded companies.
The patient population and the status quo
The disease state here is financial toxicity, a side effect of the U.S. healthcare system that impacts nearly every patient facing non-emergency care. The population is anyone with commercial insurance or a high-deductible plan who must shop for scheduled services,from imaging to outpatient surgery.
The standard of care today is a frustrating blend of guesswork and post-hoc disputes. A patient typically calls their insurer for a cost estimate, which may be a non-binding quote based on incomplete data. They might search a hospital’s PDF price list, an exercise in frustration. After the service, they receive a bill filled with codes and adjustments, often leading to calls with the provider’s billing department to contest charges. Rede’s bet is that showing a sourced, plan-specific price upfront,and providing a tool to decode the subsequent bill,can short-circuit this stressful, time-consuming process. It is a bet on transparency as a therapeutic in itself.
The roadmap from waitlist to impact
Currently, rede.care has opened a waitlist for test users, investors, and partners [rede.care, retrieved 2024]. The next twelve months will be critical in moving from a demonstrated concept to a functional product. Key milestones to watch will be the onboarding of its first cohort of test users, the publication of a detailed methodology for its data sourcing, and any announced partnerships with data aggregators or patient advocacy groups. As a pre-seed venture with no disclosed funding, the company’s ability to attract capital will be a direct test of investor belief in this specific, honesty-first approach to price navigation. For patients, the real test is simpler: can it turn a published price file into a confident decision.
Sources
- [rede.care, retrieved 2024] Rede: See the real price before you get the bill | https://rede.care
- [LinkedIn, retrieved 2024] Andrew Magown - Founder & CEO - Rede | https://www.linkedin.com/in/amagown